interferon - 500 Beiträge pro Seite
eröffnet am 25.05.01 13:27:33 von
neuester Beitrag 01.07.01 10:48:50 von
neuester Beitrag 01.07.01 10:48:50 von
Beiträge: 6
ID: 409.589
ID: 409.589
Aufrufe heute: 0
Gesamt: 549
Gesamt: 549
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 10:56 | 5805 | |
| vor 30 Minuten | 5795 | |
| vor 36 Minuten | 3526 | |
| heute 09:20 | 2561 | |
| vor 29 Minuten | 1833 | |
| vor 13 Minuten | 1710 | |
| vor 23 Minuten | 1293 | |
| vor 49 Minuten | 1083 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.947,43 | +0,26 | 206 | |||
| 2. | 4. | 3,8900 | +5,14 | 74 | |||
| 3. | 3. | 8,2700 | -0,24 | 74 | |||
| 4. | 2. | 172,30 | +0,30 | 60 | |||
| 5. | 14. | 0,0163 | +1,88 | 49 | |||
| 6. | 6. | 6,6280 | -0,78 | 38 | |||
| 7. | 5. | 0,1895 | -2,07 | 37 | |||
| 8. | 9. | 0,9750 | +1,04 | 36 |
Feedback
wer hat news zu interferon sciences??
komisch,keine umsätze,dabei forschen sie an einem aidsmittel,krige keine zu 0,55 euro
Interferon Sciences Receives Exclusive License From Mayo Foundation for Medical Education and Research for Novel Approach to Prevent Recurrence of Tumors After Cancer SurgeryISI Will Provide Study Drug And Fund Clinical Research That Could Enhance T
NEW BRUNSWICK, N.J., May 14, 2001 (BW HealthWire) -- Interferon Sciences, Inc.
(ISI) (OTC-BB:IFSC) announced that it has signed an exclusive technology license
agreement with Mayo Foundation for Medical Education and Research, of Rochester,
MN, for the rights to technology under investigation for preventing the
recurrence of cancer after surgical removal of tumors.
The approach, referred to as neo-adjuvant immunotherapy with interferon, is
being developed at Mayo Clinic by Svetomir N. Markovic, M.D, Ph.D., Assistant
Professor of Oncology at Mayo Medical School. It is based upon encouraging
preclinical studies in which natural murine (mouse) leukocyte interferon was
used to pre-treat mice in order to stimulate their immune systems prior to
surgical resection of their tumors (murine melanoma).
The animal studies showed that short duration pre-treatment with interferon in
the neo-adjuvant protocol significantly increased the percentage of survival
compared to untreated controls (56% vs. 0%). Animals treated with interferon for
the same duration immediately after surgery (adjuvant therapy) did no better
than the untreated controls. It is unknown whether comparable results can be
achieved in humans.
As part of the collaboration with Mayo, Interferon Sciences will fund a clinical
trial entitled "Identification of an Immunostimulatory Dose of Natural
Interferon (Phase A) and Its Impact on Clinical Outcome (Phase B) in Patients
with Melanoma", and supply its human leukocyte derived alpha interferon as the
study drug.
With regard to this study, Dr. Markovic commented, "I am looking forward to
conducting this trial to continue our investigation in humans of the potential
of this exciting new immunotherapeutic approach -- neo-adjuvant natural
interferon for the prevention of metastatic recurrences."
"If this neo-adjuvant immunotherapy approach with human leukocyte derived alpha
interferon is ultimately found to be successful in extending the disease-free
interval after surgery, it would not only extend survival of these patients, but
also enhance their quality of life," commented James R. Knill, M.D., Vice
President of Medical Affairs for Interferon Sciences.
Interferon Sciences, Inc. is a biopharmaceutical company engaged in the study,
manufacture and sale of pharmaceutical products based on its highly purified,
natural-source, multi-species alpha interferon. The Company`s ALFERON N
Injection(R) (Interferon Alfa-n3) product has been approved by the United States
Food and Drug Administration for the treatment of certain types of genital
warts, and is being studied for potential use in other indications, including
cancer and multiple sclerosis. In addition, the Company is seeking to enter into
collaborations with companies in the areas of cancer, infectious diseases, and
immunology. The Company`s strategy is to utilize its expertise in regulatory
affairs, clinical trials, manufacturing, and research and development to acquire
equity participations in early stage companies. The Company recently announced
the acquisition of 43% of Metacine, Inc., a company developing anti-cancer
vaccines based on dendritic cell technology.
The forward-looking statements contained herein reflect ISI management`s current
views with respect to future events and financial performance. These
forward-looking statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements, all of which are difficult to predict and many of
which are beyond the control of ISI, including, those risks and uncertainties
detailed in the Company`s periodic reports and registration statements filed
with the Securities and Exchange Commission.
NEW BRUNSWICK, N.J., May 14, 2001 (BW HealthWire) -- Interferon Sciences, Inc.
(ISI) (OTC-BB:IFSC) announced that it has signed an exclusive technology license
agreement with Mayo Foundation for Medical Education and Research, of Rochester,
MN, for the rights to technology under investigation for preventing the
recurrence of cancer after surgical removal of tumors.
The approach, referred to as neo-adjuvant immunotherapy with interferon, is
being developed at Mayo Clinic by Svetomir N. Markovic, M.D, Ph.D., Assistant
Professor of Oncology at Mayo Medical School. It is based upon encouraging
preclinical studies in which natural murine (mouse) leukocyte interferon was
used to pre-treat mice in order to stimulate their immune systems prior to
surgical resection of their tumors (murine melanoma).
The animal studies showed that short duration pre-treatment with interferon in
the neo-adjuvant protocol significantly increased the percentage of survival
compared to untreated controls (56% vs. 0%). Animals treated with interferon for
the same duration immediately after surgery (adjuvant therapy) did no better
than the untreated controls. It is unknown whether comparable results can be
achieved in humans.
As part of the collaboration with Mayo, Interferon Sciences will fund a clinical
trial entitled "Identification of an Immunostimulatory Dose of Natural
Interferon (Phase A) and Its Impact on Clinical Outcome (Phase B) in Patients
with Melanoma", and supply its human leukocyte derived alpha interferon as the
study drug.
With regard to this study, Dr. Markovic commented, "I am looking forward to
conducting this trial to continue our investigation in humans of the potential
of this exciting new immunotherapeutic approach -- neo-adjuvant natural
interferon for the prevention of metastatic recurrences."
"If this neo-adjuvant immunotherapy approach with human leukocyte derived alpha
interferon is ultimately found to be successful in extending the disease-free
interval after surgery, it would not only extend survival of these patients, but
also enhance their quality of life," commented James R. Knill, M.D., Vice
President of Medical Affairs for Interferon Sciences.
Interferon Sciences, Inc. is a biopharmaceutical company engaged in the study,
manufacture and sale of pharmaceutical products based on its highly purified,
natural-source, multi-species alpha interferon. The Company`s ALFERON N
Injection(R) (Interferon Alfa-n3) product has been approved by the United States
Food and Drug Administration for the treatment of certain types of genital
warts, and is being studied for potential use in other indications, including
cancer and multiple sclerosis. In addition, the Company is seeking to enter into
collaborations with companies in the areas of cancer, infectious diseases, and
immunology. The Company`s strategy is to utilize its expertise in regulatory
affairs, clinical trials, manufacturing, and research and development to acquire
equity participations in early stage companies. The Company recently announced
the acquisition of 43% of Metacine, Inc., a company developing anti-cancer
vaccines based on dendritic cell technology.
The forward-looking statements contained herein reflect ISI management`s current
views with respect to future events and financial performance. These
forward-looking statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements, all of which are difficult to predict and many of
which are beyond the control of ISI, including, those risks and uncertainties
detailed in the Company`s periodic reports and registration statements filed
with the Securities and Exchange Commission.
will mir keiner 10000 stück zu 0,52 verkaufen??
INTERFERON im OKTOBER BEI 10 EURO!!!
SRENG GEHEIMES MEDIKAMENT KOMMT AUF DEN MARKT!
SRENG GEHEIMES MEDIKAMENT KOMMT AUF DEN MARKT!
Trading Spotlight
hallo,kaufen oder nachkaufen sollte man erst bei einer doppelbodenbildung von 0,31 euro.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 205 | ||
| 86 | ||
| 74 | ||
| 73 | ||
| 42 | ||
| 39 | ||
| 36 | ||
| 33 | ||
| 30 | ||
| 24 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 | ||
| 14 | ||
| 13 | ||
| 12 |
